Drugs / MK-2225
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06643390 | Nov 2023 → Jul 2025 | systemic sclerosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04948554 | Mar → Oct 2023 | systemic sclerosis | Acceleron Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06643390 ↗ |
| Known as | ACE-1334 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314992 ↗ |
| Route | Subcutaneous | “Administered Subcutaneously (SC)” NCT04948554 ↗ |